Equities Analysts Issue Forecasts for AXSM FY2026 Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Axsome Therapeutics in a report released on Monday, June 9th. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the company will earn ($0.41) per share for the year. Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for Axsome Therapeutics' current full-year earnings is ($2.79) per share.

Other analysts have also issued research reports about the company. Wells Fargo & Company restated an "overweight" rating and issued a $165.00 price objective (up previously from $160.00) on shares of Axsome Therapeutics in a research note on Tuesday, May 6th. Royal Bank of Canada dropped their price target on shares of Axsome Therapeutics from $193.00 to $186.00 and set an "outperform" rating for the company in a research report on Thursday. Needham & Company LLC cut their target price on Axsome Therapeutics from $153.00 to $150.00 and set a "buy" rating for the company in a research report on Monday. Morgan Stanley raised their price target on Axsome Therapeutics from $125.00 to $190.00 and gave the stock an "overweight" rating in a research report on Thursday, February 27th. Finally, Truist Financial boosted their price target on Axsome Therapeutics from $190.00 to $200.00 and gave the company a "buy" rating in a research note on Wednesday, February 19th. One investment analyst has rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $172.33.

Axsome Therapeutics Stock Down 2.0%

Shares of NASDAQ AXSM traded down $2.15 during trading hours on Tuesday, hitting $104.10. The company had a trading volume of 425,883 shares, compared to its average volume of 676,588. Axsome Therapeutics has a 1-year low of $71.15 and a 1-year high of $139.13. The company has a quick ratio of 2.04, a current ratio of 2.11 and a debt-to-equity ratio of 3.22. The firm's 50 day moving average is $106.45 and its 200-day moving average is $106.95. The stock has a market capitalization of $5.13 billion, a P/E ratio of -17.38 and a beta of 0.47.

Insider Transactions at Axsome Therapeutics

In other Axsome Therapeutics news, Director Mark Coleman sold 3,750 shares of the firm's stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $105.47, for a total value of $395,512.50. Following the sale, the director now owns 50,387 shares in the company, valued at $5,314,316.89. This trade represents a 6.93% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, COO Mark L. Jacobson sold 25,000 shares of the company's stock in a transaction on Monday, June 9th. The stock was sold at an average price of $110.44, for a total transaction of $2,761,000.00. Following the transaction, the chief operating officer now owns 5,783 shares of the company's stock, valued at $638,674.52. This trade represents a 81.21% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 72,423 shares of company stock valued at $7,711,619. 22.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Axsome Therapeutics

Hedge funds have recently modified their holdings of the company. Strategic Financial Concepts LLC acquired a new position in shares of Axsome Therapeutics in the fourth quarter valued at approximately $2,599,000. Principal Financial Group Inc. grew its holdings in Axsome Therapeutics by 6,002.7% during the 4th quarter. Principal Financial Group Inc. now owns 207,065 shares of the company's stock worth $17,520,000 after acquiring an additional 203,672 shares during the last quarter. Peregrine Capital Management LLC increased its position in Axsome Therapeutics by 21.2% in the 4th quarter. Peregrine Capital Management LLC now owns 87,187 shares of the company's stock valued at $7,377,000 after acquiring an additional 15,258 shares during the period. New York State Common Retirement Fund raised its stake in shares of Axsome Therapeutics by 64.8% during the fourth quarter. New York State Common Retirement Fund now owns 22,491 shares of the company's stock valued at $1,903,000 after acquiring an additional 8,843 shares during the last quarter. Finally, IFP Advisors Inc raised its stake in shares of Axsome Therapeutics by 36.2% during the fourth quarter. IFP Advisors Inc now owns 67,839 shares of the company's stock valued at $5,740,000 after acquiring an additional 18,038 shares during the last quarter. Institutional investors and hedge funds own 81.49% of the company's stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.